Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Faron Pharmaceuticals Oy (FARON)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.81 +0.05    +2.84%
30/04 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Finland
ISIN:  FI4000153309 
S/N:  72007497
  • Volume: 86,202
  • Bid/Ask: 1.81 / 1.82
  • Day's Range: 1.76 - 1.85
Faron Pharmaceuticals Oy 1.81 +0.05 +2.84%

Faron Pharmaceuticals Oy Company Profile

 
Get an in-depth profile of Faron Pharmaceuticals Oy, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

34

Equity Type

ORD

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Contact Information

Address Joukahaisenkatu 6 B
Turku, 20520
Finland
Phone 358 2469 5151
Fax 358 2469 5152

Top Executives

Name Age Since Title
Jonathan Kenneth Charles Knowles 75 2015 Chairman of the Scientific Advisory Board
John Poulos 70 2017 Independent Non-Executive Director
Markku Tapani Jalkanen 70 2006 Founder, CEO & Executive Director
Huaizheng Peng 62 2015 Board Observer
Christophe Massard - 2019 Member of the Scientific Advisory Board
David Adams - 2019 Member of the Scientific Advisory Board
Marie-Louise Helena Fjallskog 60 2022 Independent Non-Executive Director
Christine Ann Roth 61 2023 Independent Non-Executive Director
Sirpa Jalkanen 70 2019 Member of the Scientific Advisory Board
Tyler Curiel - 2021 Member of the Scientific Advisory Board
Tuomo Patsi 60 2023 Independent Non-Executive Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FARN Comments

Write your thoughts about Faron Pharmaceuticals Oy
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Teemu Kyttälä
Teemu Kyttälä Oct 13, 2023 6:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2024 Bayer will buy this for aprox. 5B EUR
Pema Zangmo
Pema Zangmo Mar 23, 2021 11:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looks promising indeed
Katja Ko
Katja Ko Mar 22, 2021 4:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good news for Faron: https://news.cision.com/faron-pharmaceuticals-oy/r/bexmarilimab--clevegen--development-update,c3311200
Neek Kajula
Neek Kajula Feb 26, 2021 7:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
maybe if it touches 3 K will buy. I'm more after the tech discounts in US markets
Neek Kajula
Neek Kajula Feb 26, 2021 7:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Neek Kajula
Neek Kajula Feb 25, 2021 4:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Soon a buy?
Marko Koskinen
Marko Koskinen Feb 01, 2021 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Holding with this still
Tommi Nuutinen
Tommi Nuutinen Jan 25, 2021 1:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sold of. Boucht Nokia instead
Tommi Nuutinen
Tommi Nuutinen Jan 20, 2021 5:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice. Best finnish stock this week(and hopefully it continues this kind of surge.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email